含氟达拉滨的联合化疗对淋巴瘤合并溶血性贫血患者预后的影响

摘要

目的：探讨含氟达拉滨的联合化疗对淋巴瘤合并溶血性贫血患者预后的影响。方法选取2014年1月至2015年3月于接受化疗的淋巴瘤合并溶血性贫血患者110例。根据病理类型分为慢性淋巴细胞白血病/小淋巴细胞淋巴（CLL/ SLL）33例，滤泡性淋巴瘤（FL）39例，黏膜相关淋巴组织淋巴瘤（ MALT）38例。随机分为两组：FLU 组55例，采用以氟达拉滨+米托蒽醌+地塞米松联合化疗；CHOP 组55例，采用环磷酰胺+表阿霉素+长春新碱+泼尼松联合化疗。比较两组不同病理类型的化疗效果、3年生存率（3- yOS）和3年无进展生存率（3- yPFS）值以及不良反应发生情况。结果 CLL/ SLL、FL 和 MALT 病理类型下，FLU 组与 CHOP 组的 CR 率和 CR + PR 率，经统计学比较，无显著性差异（ P >0.05）。在 FL 和 MALT 类型下，FLU 组与 CHOP 组的3- yOS 和3- yPFS 值，无显著性差异（ P >0.05）；在CLL/ SLL 类型下，FLU 组的3- yOS 和3- yPFS 值显著高于 CHOP 组，差异具有统计学意义（ P 0. 05) in CLL / SLL,FL and MALT. 3 - yPFS value in the FL and MALT type,3 - yOS FLU group and CHOP group did not have significant difference ( P > 0. 05). In CLL/ SLL type,3 - yOS FLU group and 3 - yPFS value significantly higher than CHOP group,the difference was statistically significant( P < 0. 05). Two main side effects included myelosuppression and infection performance,adverse FLU group were higher than CHOP group. In FL histological type,FLU group incidence of infection and bone marrow suppression were significantly higher than CHOP group( P <0. 05). Cniclusini Fluorine fludarabine combination chemotherapy for lymphoma with hemolytic anemia good effect,with a higher survival ad-vantage,the high rate of adverse reactions.